Phytohealth Corporation AI Stock Analysis
Phytohealth Corporation (4108) AI Stock Analysis
Phytohealth Corporation
(TWSE:4108)
The overall score is very low, driven primarily by a deeply unprofitable and cash-burning core business. The company suffers from declining revenue and collapsing margins, which translate into persistent operating losses. While the balance sheet is a fortress with minimal debt and substantial equity, it is being slowly depleted. Technical trends confirm bearish momentum, with the stock trading below all major moving averages. The negative P/E ratio and lack of a dividend further diminish any investment case. The company's viability hinges entirely on a successful operational turnaround before its financial cushion runs out.
Phytohealth Corporation (4108) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.07B
- Dividend Yield
- ―
- Average Volume (3M)
- 282.44K
- Price to Earnings (P/E)
- -48.4
- Beta (1Y)
- 0.43
- Revenue Growth
- 1.10%
- EPS Growth
- 54.83%
- Country
- TW
- Employees
- 84
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Phytohealth Corporation Business Overview & Revenue Model
Company Description
Established in 1998 and headquartered in Taipei, Taiwan, PhytoHealth Corporation specializes in the research, development, production, and commercialization of a diverse portfolio including pharmaceutical products, cosmetic lines, specific over-the-c...
Phytohealth Corporation Financial Statement Overview
Summary
Financial performance is critically weak. The income statement shows declining revenue, collapsing gross margins (30.7%), and deep net losses ($58.2M). Cash flow is persistently negative, with a $39.7M operating cash burn. The only support is a strong balance sheet with $1.87B in equity and minimal debt, which provides a runway but is being steadily eroded by unprofitable operations.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 143.43M | 134.58M | 153.56M | 162.49M | 135.47M | 168.94M |
| Gross Profit | 47.47M | 41.29M | 64.01M | 67.64M | 57.03M | 78.31M |
| EBITDA | -134.26M | -60.66M | -54.86M | -20.70M | -61.97M | -42.30M |
| Net Income | -43.37M | -58.20M | -73.50M | -47.12M | -115.03M | -78.02M |
Balance Sheet | ||||||
| Total Assets | 2.41B | 2.35B | 2.44B | 2.35B | 2.36B | 2.47B |
| Cash, Cash Equivalents and Short-Term Investments | 1.00B | 1.07B | 1.08B | 1.27B | 1.36B | 1.41B |
| Total Debt | 21.27M | 15.73M | 18.34M | 28.11M | 30.19M | 30.93M |
| Total Liabilities | 58.22M | 59.42M | 71.29M | 79.85M | 87.17M | 81.56M |
| Stockholders Equity | 1.94B | 1.87B | 1.90B | 1.93B | 1.91B | 1.98B |
Cash Flow | ||||||
| Free Cash Flow | -19.55M | -45.26M | -55.18M | -59.50M | -61.55M | -81.45M |
| Operating Cash Flow | -15.14M | -39.72M | -50.13M | -54.77M | -59.95M | -68.24M |
| Investing Cash Flow | 3.50M | 114.82M | -135.14M | 26.25M | 76.92M | -581.14M |
| Financing Cash Flow | -10.84M | -11.04M | 145.24M | -9.18M | -10.52M | 682.23M |
Phytohealth Corporation Peers Comparison
Overall Rating
TW:843285Outperform
TW:474753Neutral- TW:410841Neutral
TW:416841Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:8432 | 85Outperform | TWD 2.35B | 11.23 | ― | 4.26% | 20.56% | 67.85% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4747 | 53Neutral | TWD 1.43B | -25.70 | ― | 3.33% | 4.56% | -172.55% |
| TW:4108 | 41Neutral | TWD 2.07B | -48.44 | ― | ― | 1.10% | 54.83% |
| TW:4168 | 41Neutral | TWD 2.28B | -8.32 | ― | ― | -46.75% | -18.83% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4108 | Phytohealth Corporation | 10.40 | -4.05 | -28.03% | |
| TW:4168 | GlycoNex, Inc. | 20.30 | -1.25 | -5.80% | |
| TW:4747 | Johnson Chemical Pharmaceutical Works Co., Ltd. | 15.75 | -15.19 | -49.09% | |
| TW:7860 | Teh Seng Pharmaceutical Mfg Co Ltd | 77.80 | 7.23 | 10.24% | |
| TW:7888 | Libo Pharma Corp. | 22.90 | -22.25 | -49.28% | |
| TW:8432 | TSH Biopharm Corp. Ltd. | 61.30 | 10.91 | 21.64% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026